研发创新
R&d innovation
  • ScRNA-seq unveils the functional characteristics of glioma-associated macrophages and the regulatory effects of chlorogenic acid on the immune microenvironment-a study based on mouse models and clinical practice
    ScRNA-seq unveils the functional characteristics of glioma-associated macrophages and the regulatory effects of chlorogenic acid on the immune microenvironment-a study based on mouse models and clinical practice
    2025.01.10
    这篇论文研究了绿原酸(Chlorogenic Acid, CHA)对胶质瘤(Glioma)免疫微环境的调节作用,以及其在小鼠模型和临床实践中的潜在应用。研究通过单细胞RNA测序(scRNA-seq)揭示了胶质瘤相关巨噬细胞(Tumor-Associated Macrophages, TAMs)的亚群和功能特征,并探讨了CHA对免疫微环境的调节作用及其临床应用潜力。
  • Target fishing and mechanistic insights of the natural anticancer drug candidate chlorogenic acid
    Target fishing and mechanistic insights of the natural anticancer drug candidate chlorogenic acid
    2024.07.10
    该研究通过开发绿原酸光亲和探针结合前沿的化学生物学技术,深入揭示了线粒体乙酰辅酶A乙酰基转移酶1(ACAT1)作为绿原酸关键靶蛋白的重要角色。研究团队综合运用了组学、分子生物学、细胞生物学和结构生物学等多学科技术手段,对绿原酸与ACAT1的相互作用机制进行了全面而系统地研究,为绿原酸在癌症治疗领域的临床应用奠定了理论与实验基础。
  • ACAT1 Induces the Differentiation of Glioblastoma Cells by Rewiring Choline Metabolism
    ACAT1 Induces the Differentiation of Glioblastoma Cells by Rewiring Choline Metabolism
    2024.01.05
    绿原酸作为一种天然小分子化合物,通过抑制ACAT1的磷酸化,能够有效诱导GBM细胞的分化,具有作为胶质瘤治疗药物的潜力。
  • Cancer Differentiation Inducer Chlorogenic Acid Suppresses PD-L1 Expression and Boosts Antitumor Immunity of PD-1 Antibody
    Cancer Differentiation Inducer Chlorogenic Acid Suppresses PD-L1 Expression and Boosts Antitumor Immunity of PD-1 Antibody
    2024.01.04
    该研究聚焦于绿原酸(CHA)在癌症免疫治疗中的作用,发现CHA可作为小分子免疫检查点抑制剂,通过诱导分化,抑制癌细胞上PD-L1的表达,有效促进肿瘤中浸润T细胞,增强抗PD-1抗体的抗肿瘤效果,有望成为与抗PD-1抗体联合使用、增强抗癌免疫治疗效果的有潜力药物。
  • Chlorogenic Acid Induced Neuroblastoma Cells Differentiation via the ACAT1-TPK1-PDH Pathway
    Chlorogenic Acid Induced Neuroblastoma Cells Differentiation via the ACAT1-TPK1-PDH Pathway
    2023.06.14
    本研究揭示了绿原酸通过ACAT1-TPK1-PDH途径诱导神经母细胞瘤细胞分化的机制。研究发现,绿原酸在体内外均能诱导神经母细胞瘤细胞系(如Be(2)-M17和SH-SY5Y)的分化。其机制涉及抑制线粒体乙酰辅酶A乙酰转移酶(ACAT1)的活性。ACAT1的敲低或抑制可上调硫胺素焦磷酸激酶1(TPK1)的表达,进而激活硫胺素代谢途径,增强丙酮酸脱氢酶(PDH)的活性。
  • Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up
    Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up
    2023.05.20
    本文是一项关于注射用绿原酸治疗复发性高级别胶质瘤的I期临床研究,旨在评估其安全性、耐受性、药代动力学特征及初步抗肿瘤活性。研究方法本研究为非随机、开放标签、剂量递增的I期临床试验,共纳入26例复发性高级别胶质瘤患者,接受不同剂量(2-5.5mg/kg)的绿原酸肌肉注射,并进行长达5年的随访。研究结果显示绿原酸耐受性良好,最大耐受剂量为5.5mg/kg。